Form 4: Lyra Therapeutics Director C. Ann Merrifield Acquires Stock Options
SEC Form 4 Filing
Director C. Ann Merrifield acquired stock options in Lyra Therapeutics, Inc. on June 13, 2024.
Summary
- C. Ann Merrifield, a director of Lyra Therapeutics, Inc., filed a Form 4 on June 14, 2024, reporting a transaction.
- On June 13, 2024, Merrifield acquired 30,000 stock options with an exercise price of $0.31.
- These options vest on the earlier of June 13, 2025, or the day before the next annual meeting of stockholders after the grant date, contingent on continued service as a non-employee director.
- Following the transaction, Merrifield directly owns 30,000 derivative securities (stock options).
Sentiment
Score: 5
Explanation: The document is a standard regulatory filing detailing an insider transaction. It doesn't inherently convey positive or negative sentiment.
Industry Context
This filing is a routine disclosure of insider transactions, which are common in publicly traded companies. It provides transparency into the actions of company directors.
Stakeholder Impact
- The transaction provides transparency to shareholders regarding director compensation and ownership.
Key Dates
| Date | Description |
|---|---|
| 06/13/2024 | Date of stock option transaction |
| 06/14/2024 | Date Form 4 was filed |
| 06/13/2025 | Earliest vesting date for stock options |
| 06/12/2034 | Expiration date for stock options |
Keywords
Form 4, Lyra Therapeutics, Stock Options, Director, Beneficial Ownership, Securities
Disclaimer:The information provided here is for general informational purposes only and does not constitute financial advice, recommendation, or endorsement of any kind. It may contain errors or omissions. You should not rely on this information to make financial decisions. Always seek the advice of a qualified financial professional before making any investment or financial decisions. Use of this information is at your own risk.